Our capital ventures include funding for the following health start-ups across the globe.
Targets an annual dividend yield of 5% of the net asset value (NAV) with the potential for special dividends, though these are not guaranteed.
A mix of debt and equity investments provides investors with a different risk-return profile to equity alone.
The portfolio has around 4 smaller companies across the biotech industry.
The portfolio is focused on innovative health & biotech companies that have a long-term potential.
Past performance is not a reliable indicator of future results and may not be repeated. Dividends are not guaranteed.
| Year to December 31 | Annual Total Return | Annual Dividend Yield |
|---|---|---|
| 2020 | 3.4% | 1.8% |
| 2021 | 11.7% | 5% |
| 2022 | 14.2% | 7.3% |
| 2023 | 13.6% | 6.8% |
See our latest posts on investing, raising capital and risk management
Fintech has emerged as one of the most disruptive and exciting sectors in the venture capital (VC) landscape, reshaping how consumers and businesses interact with financial services. From digital banking … Continued
Read more
